|Over a week ago|
Sophia Genetics sees FY21 revenue over $39M, consensus $37.31M 07:1809/0909/09/21
Sophia Genetics reports Q2 EPS (31c), consensus (39c) » 07:1709/0909/09/21
Reports Q2 revenue…
Reports Q2 revenue $10.2M, consensus $8.6M. "We had solid execution across our business during Q2, growing top line revenue more than 70% over the prior year period," said CEO Jurgi Camblong. "I am encouraged by our growing customer base as well as the increasing enthusiasm around for the impacts data driven medicine can have on patient outcomes. Overall, I am so proud of what we have achieved at SOPHiA and even more excited for what lies ahead. We are committed to unlocking data siloes, leveraging AI to generate actionable insights from data, and helping healthcare professionals work together as a community and deploy their collective expertise for the benefit of patients around the world."
Sophia Genetics and Dasa expand partnership to offer HRD analytics solution » 09:0208/2408/24/21
Dasa, the largest…
Dasa, the largest integrated healthcare network in Brazil, expanded its partnership with SOPHiA GENETICS to offer the first decentralized HRD, or Homologous recombination deficiency, analytics solution in Latin America. HRD is a complex biomarker, important for PARP inhibitors, that helps identify whether cancer patients may respond better to specific treatments, and its use could ultimately lead to personalized therapies that benefit the individual patient. Renowned in Brazil and abroad, Dasa serves more than 20M patients per year
|Over a month ago|
Cowen starts 'emerging leader' Sophia Genetics with Outperform » 10:3108/1708/17/21
Cowen analyst Doug…
Cowen analyst Doug Schenkel initiated coverage of Sophia Genetics with an Outperform rating and no price target. Sophia is an "emerging leader" in the decentralization of comprehensive genetic testing and the company seeks to expand into adjacencies, such as proteomics, Schenkel tells investors in a research note. The analyst sees more revenue per lab with the company's existing global network of customers via menu expansion and intra-customer sales additions.
Fly Intel: Top five analyst initiations » 09:5608/1708/17/21
CTKB, GAMB, OB, SOPH, CRBU
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cytek Biosciences (CTKB) initiated with an Overweight at Piper Sandler. 2. Gambling.com (GAMB) initiated with a Buy at Truist, Stifel and Jefferies. 3. Outbrain (OB) initiated with a Buy at Citi, and Needham, initiated with an Outperform at JMP Securities, and Evercore ISI and initiated with a Hold at Jefferies. 4. Sophia Genetics (SOPH) initiated with an Overweight at JPMorgan and an Outperform at Cowen. 5. Caribou Biosciences (CRBU) initiated with a Buy at BofA, a Neutral at Citi and an Outperform at SVB Leerink. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
Sophia Genetics initiated with Overweight, $23 target at JPMorgan » 08:4708/1708/17/21
JPMorgan analyst Tycho…
JPMorgan analyst Tycho Peterson initiated coverage of Sophia Genetics with an Overweight rating and $23 price target. As a "first mover with leading scale and accuracy," as well as multiple future expansion opportunities, Sophia is positioned to drive "durable high" revenue growth, and its software-as-a-service model confers significant operating leverage over time, Peterson tells investors in a research note. He believes the stock's current valuation "leaves meaningful upside."
Morgan Stanley starts Sophia Genetics at Overweight with $24 price target » 07:5608/1708/17/21
As previously reported,…
As previously reported, Morgan Stanley analyst Tejas Savant initiated coverage of Sophia Genetics with an Overweight rating and $24 price target. Sophia's "highly differentiated," cloud-based informatics platform is easy to deploy, affordable to access and capable of enabling precision medicine at scale, said Savant, who projects a "robust" top-line compound annual growth rate of about 40% through 2025.
Sophia Genetics initiated with an Outperform at Cowen » 06:1908/1708/17/21
Cowen analyst Doug…
Cowen analyst Doug Schenkel initiated coverage of Sophia Genetics with an Outperform rating.
Sophia Genetics initiated with an Overweight at JPMorgan » 06:1808/1708/17/21
JPMorgan analyst Tycho…
JPMorgan analyst Tycho Peterson initiated coverage of Sophia Genetics with an Overweight rating and $23 price target.
Sophia Genetics initiated with an Overweight at Morgan Stanley » 06:1608/1708/17/21
Morgan Stanley analyst…
Morgan Stanley analyst Tejas Savant initiated coverage of Sophia Genetics with an Overweight rating and $24 price target.